West Pharmaceutical Services (NYSE:WST) vs. Straumann (OTCMKTS:SAUHY) Head to Head Contrast

Straumann (OTCMKTS:SAUHY) and West Pharmaceutical Services (NYSE:WST) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Straumann and West Pharmaceutical Services, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Straumann	1	2	1	3	2.86
West Pharmaceutical Services	0	4	9	2	2.87

West Pharmaceutical Services has a consensus price target of $349.20, indicating a potential upside of 26.92%. Given West Pharmaceutical Services’ stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Straumann.

Dividends

Straumann pays an annual dividend of $0.03 per share and has a dividend yield of 0.3%. West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.3%. West Pharmaceutical Services pays out 13.0% of its earnings in the form of a dividend.

Insider and Institutional Ownership

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.5% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Straumann and West Pharmaceutical Services”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Straumann	$2.84 billion	6.73	$441.09 million	N/A	N/A
West Pharmaceutical Services	$3.02 billion	6.56	$492.70 million	$6.75	40.76

West Pharmaceutical Services has higher revenue and earnings than Straumann.

Profitability

This table compares Straumann and West Pharmaceutical Services’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Straumann	N/A	N/A	N/A
West Pharmaceutical Services	16.29%	18.16%	13.45%

Volatility and Risk

Straumann has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Straumann on 11 of the 15 factors compared between the two stocks.

About Straumann

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implants and components made from titanium, titanium alloy, and ceramics; prosthetic elements made od ceramics, metal or polymer; and clear aligners. In addition, it offers resins for 3D printing and thermoplastics for clear aligner production; and biomaterials for tissue generation. Further, it provides digital equipment comprising scanners, milling machines and 3D printers. Further, it offers training and education services. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.